Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study

9 Jul 2022

Abstract excerpt

BACKGROUND: Miridesap depletes circulating serum amyloid P (SAP) and dezamizumab (anti-SAP monoclonal antibody) targets SAP on amyloid deposits, triggering amyloid removal. In a phase 1, first-in-human study (FIHS), progressive amyloid removal was observed in some patients after ≤ 3 cycles of miridesap/dezamizumab. METHODS: This observational, non-interventional study in patients who received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Amyloidosis: Diagnosis, Treatment, Outcomes
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35810311
DOI: 10.1186/s13023-022-02405-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 studyPMID 35810311Read ↗

Emerging Pharmacological Strategies for Cardiac Amyloidosis: A Qualitative Analysis of Interventional Clinical Trials Registered on ClinicalTrials.govSemantic proximity Read ↗

Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.Semantic proximity Read ↗

Systemic amyloidosis journey from diagnosis to outcomes: a twelve-year real-world experience of a single center in a middle-income countrySemantic proximity Read ↗

Divergent Clinical Phenotypes, Organ Involvement, and Survival in AL Amyloidosis and Light Chain Deposition Disease: Insights From a Large Single-Center CohortSemantic proximity Read ↗

Are Pre-frail and Frail Amyloid Positive Individuals Eligible to Lecanemab? A cross-sectional analysis from the Cogfrail Real-World CohortSemantic proximity Read ↗

The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosisSemantic proximity Read ↗

Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health SystemSemantic proximity Read ↗

Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.Semantic proximity Read ↗

From stabilization to silencing in transthyretin amyloid cardiomyopathy: why sequencing should be treat-to-trajectory, not 'one-and-done'.Semantic proximity Read ↗

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple SclerosisSemantic proximity Read ↗

The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trialSemantic proximity Read ↗

A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.